← Leaderboards
Javid J Moslehi
Brigham And Women'S Hospital
$8,184,260
Attributed
$11,870,489
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2009–25$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,870,489 · 5
By mechanism
R01$10,707,240 · 3
R56$612,989 · 1
K08$550,260 · 1
Top collaborators
- Justin M Balko5 shared
- Douglas B Johnson5 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- David A. Hafler$48,350,086
- Stephanie A Shore$11,152,764
- Samia J. Khoury$10,360,565
- Til Sturmer$7,698,961
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseCardiacAffectCardiovascular SystemToxic EffectCancer TherapyOncologyTreatment StrategyMalignant NeoplasmsPrevention StrategyFunctional DisorderSignal TransductionProgramsMediatingMuscle CellsVascular Endothelial Growth FactorsBlood PressureBlood VesselsBiologicalGeneticMultidisciplinaryReceptorDesignHeart Failure
Grant awards (20)
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis$805,488
R01 · FY2025 · HL
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies$615,145
R01 · FY2025 · HL · contact PI
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis$794,337
R01 · FY2024 · HL
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies$606,001
R01 · FY2024 · HL · contact PI
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis$815,509
R01 · FY2023 · HL
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension$646,539
R01 · FY2023 · HL · contact PI
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies$618,167
R01 · FY2023 · HL · contact PI
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis$820,373
R01 · FY2022 · HL
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension$646,539
R01 · FY2022 · HL · contact PI
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies$631,885
R01 · FY2022 · HL · contact PI
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies$833,492
R01 · FY2021 · HL · contact PI
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis$832,061
R01 · FY2021 · HL
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension$680,568
R01 · FY2021 · HL · contact PI
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension$680,568
R01 · FY2020 · HL · contact PI
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension$680,568
R01 · FY2019 · HL · contact PI
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension$612,989
R56 · FY2018 · HL · contact PI
A Functional Role for Prolyl Hydroxylases (PHDs) in Cardiomyopathy$138,780
K08 · FY2012 · HL · contact PI
A Functional Role for Prolyl Hydroxylases (PHDs) in Cardiomyopathy$137,970
K08 · FY2011 · HL · contact PI
A Functional Role for Prolyl Hydroxylases (PHDs) in Cardiomyopathy$137,160
K08 · FY2010 · HL · contact PI
A Functional Role for Prolyl Hydroxylases (PHDs) in Cardiomyopathy$136,350
K08 · FY2009 · HL · contact PI